Details regarding negative test results according to test in the entire study population
| No of patients undergoing test | No (%) with negative test result | No (%) with negative test result who had confirmed TB | No (%) with negative test result who were immunocompromised | |
| QFT-Plus | 358 | 47/358 (13.1) | 17/47 (36.1) | 5/47 (10.6) |
| QFT-GIT | 600 | 66/600 (11.8) | 25/66 (37.8) | 18/66 (27.3)* |
| T-SPOT.TB | 58 | 8/58 (13.7) | 6/8 (75.0) | 5/8 (62.5)* |
| TST5 | 636 | 64/636 (10.1) | 31/64 (48.4) | 14/64 (21.9)* |
| TST10 | 636 | 106/636 (16.6) | 55/106 (51.8) | 18/106 (17.0)* |
*Includes two patients with human immunodeficiency virus infection.
QFT-GIT, QuantiFERON-TB Gold in-Tube; QFT-Plus, QuantiFERON-TB Gold Plus; TB, tuberculosis; TST, tuberculin skin test.